Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.46 |
| ▸ | PREP | P48147 | 3/20 | 0.46 |
| ▸ | FAP | Q12884 | 3/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 7/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1046070 | 1.00 | DPP4 (0.46) | DPP4PREPFAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL11113477 | 0.94 | DPP4 (0.42) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL13784784 | 0.88 | DPP4 (0.44) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL8564777 | 0.88 | DPP4 (0.46) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL8564779 | 0.88 | DPP4 (0.46) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL4327210 | 0.85 | FAP (0.41) | DPP4PREPFAPF2NPSR1 | |
| SCHEMBL4330609 | 0.85 | FAP (0.41) | DPP4PREPFAPF2NPSR1 | |
| SCHEMBL29985759 | 0.85 | PREP (0.44) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL29380104 | 0.85 | ACE (0.49) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL29874508 | 0.85 | ACE (0.49) | DPP4PREPFAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458048-B1 | A non-aqueous electrolyte and a lithium secondary battery comprising the same | SAMSUNG SDI CO LTD (KR) | 2014-11-19 | — | — | EP | claimed |
| US-20040185347-A1 | Non-aqueous electrolyte and a lithium secondary battery comprising the same | SAMSUNG SDI CO., LTD. (KR) | 2004-09-23 | — | — | US | claimed |
| EP-1458048-A1 | A non-aqueous electrolyte and a lithium secondary battery comprising the same | Samsung SDI Co., Ltd. (KR) | 2004-09-15 | — | — | EP | claimed |
| EP-1206273-A2 | PEPTIDES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2002-05-22 | — | — | EP | claimed |
| WO-2001010456-A2 | PEPTIDES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2001-02-15 | — | — | WO | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250091995-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2025-03-20 | — | — | US | disclosed |
| US-20250019418-A1 | SYSTEMS AND METHODS FOR THE PRODUCTION OF METHEMOGLOBIN AND ITS DERIVATIVES | OHIO STATE INNOVATION FOUNDATION | 2025-01-16 | — | — | US | disclosed |
| WO-2003024995-A1 | MOLECULES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2003-03-27 | — | — | WO | disclosed |
| US-20030050242-A1 | Protein polymerization inhibitors and methods of use | TRIPEP AB (SE) | 2003-03-13 | — | — | US | disclosed |
| US-20020091086-A1 | Peptides that block viral infectivity and methods of use thereof | VAHLNE ANDERS (SE) | 2002-07-11 | — | — | US | disclosed |
| EP-1207897-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING TRIPEPTIDES | TRIPEP AB (SE) | 2002-05-29 | — | — | EP | disclosed |
| EP-1206273-A2 | PEPTIDES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2002-05-22 | — | — | EP | disclosed |
| US-6258932-B1 | TRIPEPTIDE OF DEFINED AMINO ACID SEQUENCE AND HAVING A C-TERMINAL AMIDE; VIRICIDES; TREATMENT AND PREVENTION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (BE) | 2001-07-10 | — | — | US | disclosed |
| WO-2001010456-A2 | PEPTIDES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2001-02-15 | — | — | WO | disclosed |
| WO-2001010457-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING TRIPEPTIDES | TRIPEP AB (SE) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | DPP4 279/4885PREP 18/4885FAP 616/4885 |
| US-20250019418-A1 | SYSTEMS AND METHODS FOR THE PRODUCTION OF METHEMOGLOBIN AND ITS DERIVATIVES | MB, HMBS, HCCS | DPP4 3985/4885PREP 1926/4885FAP 1691/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | DPP4 340/4885PREP 518/4885FAP 1151/4885 |
| US-20250091995-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | KCNQ2, KCNQ1, KCNQ5 | DPP4 377/4885PREP 3855/4885FAP 4577/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | DPP4 139/4885PREP 153/4885FAP 1256/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | DPP4 39/4885PREP 646/4885FAP 1812/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | DPP4 75/4885PREP 645/4885FAP 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.